FDA Compounding Advisory Panel Re-formed With Many Pending Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Fourteen committee members could give advice on Good Manufacturing Practices for registered outsourcing facilities as well as help determine list of drugs that cannot be compounded.
You may also be interested in...
FDA’s Advisory Committee Schedule Hints At Re-formulated Compounding Panel
The agency has not set a meeting date for the Pharmacy Compounding Drugs Advisory Committee, defunct since 2002, in its tentative schedule, but has included 13 vacancies on the panel in its list of committees in need of new members.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.